(Q34683835)

3 August 2017

title

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program (English)

1 reference

3 August 2017

2

Richard Gorlick

1 reference

3 August 2017

12

Peter J Houghton

1 reference

3 August 2017

4

Min H Kang

1 reference

3 August 2017

8

John M Maris

1 reference

3 August 2017

13

Malcolm A Smith

1 reference

3 August 2017

11

Raushan T Kurmasheva

1 reference

3 August 2017

6

Richard Lock

1 reference

3 August 2017

1

E Anders Kolb

1 reference

3 August 2017

7

Stephen T Keir

1 reference

3 August 2017

5

Hernan Carol

1 reference

3 August 2017

9

Catherine A Billups

1 reference

3 August 2017

3

C Patrick Reynolds

1 reference

3 August 2017

author name string

Christopher Desjardins

series ordinal

10

1 reference

3 August 2017

publication date

28 March 2013

1 reference

3 August 2017

published in

Pediatric Blood Cancer

1 reference

3 August 2017

volume

60

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

1325-1332

1 reference

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Eribulin: a novel cytotoxic chemotherapy agent

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Eribulin mesylate in patients with refractory cancers: a Phase I study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Evaluation of ABT-751 against childhood cancer models in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Microtubules as a target for anticancer drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Vincristine sulfate in management of Wilms' tumor. Replacement of preoperative irradiation by chemotherapy.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4263960

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

7 July 2018

1 reference

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

21 January 2018

1 reference

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

21 January 2018

1 reference

The pediatric preclinical testing program: description of models and early testing results.

21 January 2018

1 reference

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

21 January 2018

1 reference

Vincristine sulfate therapy in children with metastatic soft tissue sarcoma

21 January 2018

1 reference

12 December 2020

Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms' tumor)

1 reference

12 December 2020

Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma

1 reference

12 December 2020

Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7)

1 reference

12 December 2020

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma

1 reference

12 December 2020

A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group

1 reference

12 December 2020

Vincristine treatment of cancer in children

1 reference

12 December 2020

VINCRISTINE IN CHILDREN WITH MALIGNANT SOLID TUMORS

1 reference

12 December 2020

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

1 reference

12 December 2020

Identifiers

DOI

10.1002/PBC.24517

1 reference

3 August 2017

1 reference

3 August 2017

1 reference